 |
|
| Company | Bristol-Myers Squibb Company |
| Headquarters | 345 Park Avenue, New York, NY 10154, USA |
| CEO | Lamberto Andreotti |
| CFO | Charles Bancroft |
| Industry | Biopharmaceuticals |
| Founder | Merger of Bristol-Myers and Squib |
| Founded | 1989 |
| Type | Public |
| NYSE stock symbol | BMY |
| Revenue | $15.879 billion (2014) |
| Net income | $ 2,029 million (2014) |
| Earnings per share | $1.20 USD (2014) |
| Employees | 25,000 (2014) |
| Website | http://bms.com |
| Investor relations contact number: | 609-252-4611 |
Bristol-Myers Squibb is an American multinational biopharmaceuticals company, based in New York City, USA.
The company focuses on discovering, developing, and manufacturing prescription pharmaceuticals for the treatment of various medical conditions, including cardiovascular disease, cancer, diabetes, psychiatric disorders, HIV/AIDS, hepatitis, and arthritis.
It is publicly listed on the New York Stock Exchange (NYSE) under the stock ticker symbol ‘BMY’.
Bristol-Myers Squibb was created in 1989 after the merger of Bristol-Myers (founded in 1887 by William McLaren Bristol and John Ripley Myers) and the Squibb Corporation (founded in 1858 by Edward Robinson Squibb).
Its mission is to “discover, develop and deliver innovative medicines that help patients prevail over serious diseases.”
Bristol-Myers Squibb’s flagship drugs are: Abilify® (2013 sales of $2.3 billion), Sustiva® franchise (2013 sales of $1.6 billion), Reyataz® (2013 sales of $1.6 billion), Baraclude® (2013 sales of $1.5 billion), Orencia® (2013 sales of $1.4 billion), Sprycel® (2013 sales of $1.3 billion), and Yervoy® (2013 sales of $960 million).
The company invests heavily in research and development (R&D), which it claims is critical to its long-term competitiveness.
Its R&D facilities are located in: San Francisco (California) , Hopewell (New Jersey), New Brunswick (New Jersey), Plainsboro (New Jersey), Princeton (New Jersey), Wallingford (Connecticut), Waltham (Massachusetts), Seattle (Washington), Rueil-Malmaison (France), Braine-L’Alleud (Belgium), Tokyo (Japan), and Moreton (England).
| Income statement data (in $ millions) | 2014* | 2013* |
| Net product sales | $11,660 | $12,304 |
| Alliance and other revenues | $4,219 | $4,081 |
| – Total Revenues | $15,879 | $16,385 |
| Cost of products sold | $3,932 | $4,619 |
| Marketing, selling and administrative | $4,088 | $4,084 |
| Advertising and product promotion | $734 | $855 |
| Research and development | $4,534 | $3,731 |
| Other (income)/expense | $210 | $205 |
| – Total Expenses | $13,498 | $13,494 |
| Earnings Before Income Taxes, EBIT | $2,381 | $2,891 |
| Provision for/(Benefit from) Income Taxes | $352 | $311 |
| Net Earnings | $2,029 | $2,580 |
| Net Earnings Attributable to Noncontrolling Interest | $25 | $17 |
| Net Earnings Attributable to Bristol-Myers Squibb | $2,004 | $2,563 |
| Balance sheet data (in $ millions) | ||
| Total assets | $33,749 | $38,592 |
| Total liabilities | $18,766 | $23,356 |
| Total Bristol-Myers Squibb Company Shareholders’ Equity | $14,852 | $15,154 |
| Common share data (in $) | ||
| Earnings per Common Share – Basic | $1.21 | $1.56 |
| Earnings per Common Share – Diluted | $1.20 | $1.54 |
| Cash flow data (in $ millions) | ||
| Net cash provided by operating activities | $3,148 | $3,545 |
| Net cash provided by (used in) investing activities | $1,216 | $(572) |
| Net cash used in financing activities | $(2,437) | $(1,068) |
| Cash and cash equivalents at beginning of year | $3,586 | $1,656 |
| Cash and cash equivalents at end of year | $5,571 | $3,586 |
*Years Ended December 31
Source: “Bristol-Myers Squibb Company Form 10-K 2014”